The project in a nutshell
Testing blocking a protein called stat3 in cells from men with
prostate cancer rather than in cells made in the laboratory.
Why we funded it
Most drugs tested in prostate cancer clinical
trials were selected on the basis of how they worked on cells that
had been grown and regrown for decades, and no longer looked or
behaved like the original tumour cells they were based on. This
research should help increase the success rate of clinical trials
for prostate cancer and provide information on the cells that are
resistant following therapy and how best to target them.
For more detailed information on this project, please look at
the lay
summary